Speaker illustration

Professor Silvio Inzucchi

New Haven ()

Interactive discussion: what are the implications of SGLT2 inhibition for CV risk reduction in a multi-risk patient population?

Event: ESC CONGRESS 2016

Topic: Diabetes management

Session: SGLT2 inhibition in the management of CV risk & T2DM: ask the experts

Thumbnail

SGLT-2 inhibitors in the management of CVD and T2DM: brief update on results of the EMPA-REG OUTCOME trial.

Event: ESC CONGRESS 2016

Topic: Diabetes management

Session: SGLT2 inhibition in the management of CV risk & T2DM: ask the experts

Thumbnail

SGLT-2 inhibitors in T2DM management: current position & future promise.

Event: ESC CONGRESS 2016

Topic: Diabetes management

Session: SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?

Thumbnail

This platform is supported by

logo Novo Nordisk